Adaptive Biotechnologies Corp

By person

29 insiders · 931 transactions

81.1×

Chad Robins holds 81.1 times base salary in stock. $56.69M of shares against $698.26K in salary for 2025.

Salary from the company's own proxy. The shares are what Chad Robins last reported holding, valued at $26.00, the price Common Stock was last bought or sold at on the open market here, on 26 Aug 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

VIKING GLOBAL INVESTORS LP entity

10% owner

$5.00M (1)

$302.14M (3)

−$297.14M

29,993,708

18.79%

$779.84M

+2,005%

VIKING GLOBAL PERFORMANCE LLC entity

10% owner

$5.00M (1)

$246.49M (2)

−$241.49M

30,993,708

19.42%

$805.84M

+2,075%

GOEL DAVID E.

Director

—

$112.23M (10)

−$112.23M

12,310,594

7.71%

$320.08M

—

ROBINS CHAD M

CEO and Chairman

—

$89.34M (160) scheduled

−$89.34M

2,180,518

1.37%

$56.69M

+19.3%

RUBINSTEIN JULIE

President and COO

—

$82.18M (198) scheduled

−$82.18M

377,802

0.2367%

$9.82M

—

ROBINS HARLAN S

Chief Scientific Officer

—

$63.17M (153) scheduled

−$63.17M

812,058

0.5088%

$21.11M

—

Cohen Chad M

Chief Financial Officer

$20.00K (1)

$47.01M (81) scheduled

−$46.99M

21,604

0.0135%

$561.70K

—

BENZENO SHARON

Chief Commercial Ofc Imm Med

—

$29.75M (50) scheduled

−$29.75M

221,278

0.1386%

$5.75M

—

LO FRANCIS

Chief People Officer

—

$12.69M (38) scheduled

−$12.69M

230,713

0.1446%

$6.00M

—

HILL NANCY LOUISE

EVP, Operations & Program Mana

$224.00K (4)

$11.38M (11) scheduled

−$11.15M

10,300

0.0065%

$267.80K

−77.2%

ZOLTNERS ANDRIS A

Director

—

$9.14M (1) scheduled

−$9.14M

3,621,016

2.27%

$94.15M

—

BALDO LANCE

Chief Medical Officer

—

$7.43M (25) scheduled

−$7.43M

17,171

0.0108%

$446.45K

—

SANG CHARLES

SVP, External Affairs

—

$6.49M (4) scheduled

−$6.49M

0.0000%

$0.00

—

GRIFFIN MICHELLE RENEE

Director

—

$5.88M (25) scheduled

−$5.88M

15,625

0.0098%

$406.25K

—

Pellini Michael J

Director

—

$5.27M (4) scheduled

−$5.27M

69,690

0.0437%

$1.81M

—

Taylor Stacy L

SVP and General Counsel

—

$4.79M (40) scheduled

−$4.79M

139,365

0.0873%

$3.62M

+10,620%

PISKEL KYLE

Chief Financial Officer

—

$3.74M (17) scheduled

−$3.74M

256,725

0.1609%

$6.67M

—

HERSHBERG ROBERT

Director

—

$3.42M (25) scheduled

−$3.42M

46,683

0.0293%

$1.21M

—

BOBULSKY SUSAN

Chief Commercial Officer, MRD

—

$3.27M (13) scheduled

−$3.27M

396,989

0.2487%

$10.32M

+233.2%

NEUPERT PETER M

Director

—

$3.21M (4) scheduled

−$3.21M

130,625

0.0818%

$3.40M

—

DOBMEIER ERIC

Director

—

$2.11M (11) scheduled

−$2.11M

1,504

0.0009%

$39.10K

—

PETERSON TYCHO

Chief Financial Officer

—

$2.02M (6) scheduled

−$2.02M

531,553

0.3331%

$13.82M

—

ADAMS R MARK

Chief Operating Officer

—

$1.66M (20)

−$1.66M

175,361

0.1099%

$4.56M

—

Palaniappan Jyoti

SVP, Diagnostics, T-Detect

—

$877.35K (8) scheduled

−$877.35K

9,158

0.0057%

$238.11K

—

SOOD NITIN

Chief Commercial Officer, MRD

—

$689.91K (6)

−$689.91K

214,808

0.1346%

$5.59M

—

OWEN KATEY EINTERZ

Director

—

$249.99K (1)

−$249.99K

66,100

0.0414%

$1.72M

—

THORSEN HENNING

SVP, Commercial Operations

—

29,061

0.0182%

$755.59K

—

Trigg Leslie

Director

—

25,907

0.0162%

$673.58K

—

Conroy Kevin T

Director

—

22,968

0.0144%

$597.17K

—

Adaptive Biotechnologies Corp

By person

Individual transactions

What was left out